Aditxt Inc. (ADTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aditxt Inc. stock (ADTX) is currently trading at $0.97. Aditxt Inc. PS ratio (Price-to-Sales) is 113.24. Analyst consensus price target for ADTX is $61.00. WallStSmart rates ADTX as Sell.
- ADTX PE ratio analysis and historical PE chart
- ADTX PS ratio (Price-to-Sales) history and trend
- ADTX intrinsic value — DCF, Graham Number, EPV models
- ADTX stock price prediction 2025 2026 2027 2028 2029 2030
- ADTX fair value vs current price
- ADTX insider transactions and insider buying
- Is ADTX undervalued or overvalued?
- Aditxt Inc. financial analysis — revenue, earnings, cash flow
- ADTX Piotroski F-Score and Altman Z-Score
- ADTX analyst price target and Smart Rating
Aditxt Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Aditxt Inc. (ADTX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Aditxt Inc. (ADTX) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Aditxt Inc. (ADTX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -89.10%, a shrinking business
Very expensive at 113.2x annual revenue
Very low institutional interest at 1.42%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Aditxt Inc. (ADTX) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.11) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (113.24) suggest expensive pricing. Growth concerns include Revenue Growth at -89.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -282.20%, Operating Margin at -419870.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -282.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -89.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ADTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ADTX's Price-to-Sales ratio of 113.24x trades 394% above its historical average of 22.9x (91th percentile), historically expensive. The current valuation is 17% below its historical high of 136.58x set in Mar 2026, and 25064% above its historical low of 0.45x in Sep 2024. Over the past 12 months, the PS ratio has expanded from ~66.3x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Aditxt Inc. (ADTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Aditxt Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 5,940 with 89% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 11314% of revenue (672,045) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 89% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Aditxt Inc. .
Bottom Line
Aditxt Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Aditxt Inc. (ADTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Aditxt Inc. is an innovative biotechnology company focused on advancing healthcare through its proprietary immune modulation and personalized medicine platform. The company is dedicated to enhancing immune system responses to combat chronic diseases and allergies, thereby improving patient outcomes. With a strong pipeline of therapeutic candidates backed by comprehensive research and strategic partnerships, Aditxt is strategically positioned to lead in the emerging field of immune-based therapies. By emphasizing scientific progress and patient-focused solutions, Aditxt aims to reshape the future of immunology and contribute significantly to the healthcare landscape.